39.64
price down icon0.13%   -0.05
after-market  After Hours:  39.64 
loading
QuidelOrtho Corporation stock is currently priced at $39.64, with a 24-hour trading volume of 545.95K. It has seen a -0.13% decreased in the last 24 hours and a -15.66% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $39.78 pivot point. If it approaches the $38.82 support level, significant changes may occur.
Previous Close:
$39.69
Open:
$39.49
24h Volume:
545.95K
Market Cap:
$2.65B
Revenue:
$3.00B
Net Income/Loss:
$-10.10M
P/E Ratio:
208.63
EPS:
0.19
Net Cash Flow:
$70.90M
1W Performance:
+1.33%
1M Performance:
-15.66%
6M Performance:
-36.41%
1Y Performance:
-55.29%
1D Range:
Value
$39.30
$40.41
52W Range:
Value
$37.78
$95.02

QuidelOrtho Corporation Stock (QDEL) Company Profile

Name
Name
QuidelOrtho Corporation
Name
Phone
858-552-1100
Name
Address
12544 High Bluff Drive, Suite 200, San Diego, CA
Name
Employee
1,193
Name
Twitter
@QuidelDX
Name
Next Earnings Date
2024-05-14
Name
Latest SEC Filings
Name
QDEL's Discussions on Twitter

QuidelOrtho Corporation Stock (QDEL) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-24 Downgrade JP Morgan Neutral → Underweight
Dec-11-23 Downgrade Citigroup Buy → Neutral
Dec-12-22 Upgrade Citigroup Neutral → Buy
Dec-07-22 Initiated RBC Capital Mkts Outperform
Oct-14-22 Upgrade UBS Sell → Neutral
Sep-19-22 Initiated Citigroup Neutral
Jul-20-22 Initiated UBS Sell
Jun-17-22 Resumed JP Morgan Neutral
Feb-22-22 Upgrade Raymond James Outperform → Strong Buy
Jan-22-21 Upgrade Raymond James Mkt Perform → Outperform
May-12-20 Downgrade JP Morgan Neutral → Underweight
Mar-26-20 Downgrade Barclays Overweight → Equal Weight
Oct-23-18 Resumed Raymond James Strong Buy
Mar-08-18 Upgrade Raymond James Outperform → Strong Buy
Jan-22-18 Reiterated Barclays Overweight
Jan-04-18 Upgrade CL King Neutral → Buy
Sep-19-17 Upgrade Piper Jaffray Neutral → Overweight
Jul-18-17 Upgrade Canaccord Genuity Hold → Buy
Jul-18-17 Upgrade William Blair Mkt Perform → Outperform
Apr-25-17 Reiterated Canaccord Genuity Hold
Feb-17-17 Initiated CL King Neutral
Dec-16-16 Downgrade Piper Jaffray Overweight → Neutral
Jun-13-16 Upgrade Raymond James Mkt Perform → Outperform
Feb-18-16 Reiterated Barclays Overweight
Feb-09-16 Downgrade Canaccord Genuity Buy → Hold
Jan-08-16 Reiterated Canaccord Genuity Buy
Dec-14-15 Downgrade Raymond James Outperform → Mkt Perform
Sep-02-15 Initiated Barclays Overweight
Jul-31-13 Reiterated Canaccord Genuity Buy
Mar-03-11 Downgrade Wedbush Outperform → Neutral
View All

QuidelOrtho Corporation Stock (QDEL) Financials Data

QuidelOrtho Corporation (QDEL) Revenue 2024

QDEL reported a revenue (TTM) of $3.00 billion for the quarter ending December 31, 2023, a -8.21% decline year-over-year.
loading

QuidelOrtho Corporation (QDEL) Net Income 2024

QDEL net income (TTM) was -$10.10 million for the quarter ending December 31, 2023, a -101.84% decrease year-over-year.
loading

QuidelOrtho Corporation (QDEL) Cash Flow 2024

QDEL recorded a free cash flow (TTM) of $70.90 million for the quarter ending December 31, 2023, a -90.48% decrease year-over-year.
loading

QuidelOrtho Corporation (QDEL) Earnings per Share 2024

QDEL earnings per share (TTM) was -$0.16 for the quarter ending December 31, 2023, a -101.29% decline year-over-year.
loading

QuidelOrtho Corporation Stock (QDEL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Busky Joseph M
Chief Financial Officer
Feb 23 '24
Buy
46.35
2,150
99,663
2,150
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
medical_devices PHG
$21.07
price up icon 1.69%
medical_devices STE
$203.90
price up icon 1.17%
$309.02
price down icon 0.48%
medical_devices ZBH
$119.35
price down icon 0.33%
$124.34
price down icon 9.91%
medical_devices EW
$86.43
price down icon 1.80%
Cap:     |  Volume (24h):